U.S. Biotech Stock News

Why GEO Group stock is back in focus GEO Group (GEO) is drawing fresh attention after US Immigration and Customs Enforcement selected the company to operate the planned Big Horn Correctional Facility in Hudson, Colorado under a six month, $39 million sole source contract. See our latest analysis for GEO Group. The contract news has arrived alongside a 9.79% year to date share price return and a 4.48% 7 day share price return, while the 1 year total shareholder return of 48.56% decline...

In its latest quarterly update, Payoneer reported revenues of US$270.9 million, up 9.1% year on year and 2.9% above analyst expectations. The company also marked more than ten consecutive quarters of rising ARPU and SMB take rates as it pushes further into higher-value, multi-product customer relationships. We’ll now explore how this continued ARPU and take rate expansion shapes Payoneer’s existing investment narrative and future earnings assumptions. Rare earth metals are the new gold rush...

SELLAS Life Sciences Group (SLS) is back on investor radars after it agreed with the IMPACT AML network to run a European clinical study of its CDK9 inhibitor, SLS009, in high risk newly diagnosed AML. See our latest analysis for SELLAS Life Sciences Group. The new IMPACT AML agreement comes after a volatile spell where traders focused on financing risk, yet the stock still shows a 74.55% 30 day share price return and a very large 1 year total shareholder return. This suggests momentum has...

IDACORP (IDA) is back on investor radar after a string of recent share price moves, with the stock up over the past week, month, and year despite a weaker past 3 months. See our latest analysis for IDACORP. That recent upswing in IDACORP’s share price, including a 7 day share price return of 4.17% and 30 day share price return of 5.27%, sits alongside a 1 year total shareholder return of 23.98%. This suggests momentum has been building over both shorter and longer horizons. If this kind of...

In early January 2026, CareTrust REIT, Inc. completed a US$142 million acquisition of six Mid-Atlantic skilled nursing facilities under a long-term triple net lease and announced a series of senior promotions and new hires across investments, asset management, legal, analytics, and accounting. This combination of portfolio expansion and reinforced in-house expertise suggests CareTrust is sharpening its focus on scaling healthcare properties while tightening operational oversight. Next, we’ll...

TMC the metals (TMC) is back in focus after news of its formal seabed mining exploration application to U.S. authorities, paired with an upcoming earnings date, has sharpened attention on the stock’s rising speculative options activity. See our latest analysis for TMC the metals. That exploration filing and the upcoming earnings date come after a volatile year, with a 30 day share price return of 7.27% and a 1 year total shareholder return above 300%. Recent speculative options activity hints...

CME Group has recently expanded its lineup with plans to introduce 100‑ounce silver futures aimed at retail traders and new futures on Cardano, Chainlink, and Stellar, while also shifting precious metals margining to a percentage-of-notional framework following heightened volatility. Together, these moves show CME Group using product design and margin policy to pull more retail and institutional activity into regulated metals and crypto markets. Next, we’ll examine how CME’s push into...

Archer’s agreement to rent two high spec drilling rigs from Patterson-UTI Energy (PTEN) for work in the Vaca Muerta shale gives investors a fresh data point on PTEN’s international drilling footprint. See our latest analysis for Patterson-UTI Energy. The Archer agreement lands after a strong run in the stock, with a 30 day share price return of 20.71% and a 90 day share price return of 29.04%. This comes even as the 1 year total shareholder return sits at a 20.75% loss and the 3 year total...

Ocugen (OCGN) shares were in focus after the company reported statistically significant 12-month data from its OCU410 Phase 2 ArMaDa trial in geographic atrophy and Phase 1 results for OCU410ST in Stargardt disease. See our latest analysis for Ocugen. Alongside the fresh OCU410 and OCU410ST data, Ocugen’s recent events, including its J.P. Morgan Healthcare Conference appearance and trial update call, have arrived during a period of strong 1 year total shareholder return of 126.57%. The 1 day...

Why RenaissanceRe Holdings (RNR) is on investors’ radar right now RenaissanceRe Holdings (RNR) has been drawing fresh attention after its Q3 2025 report highlighted much stronger underwriting income compared with Q3 2024, alongside ongoing share buybacks exceeding US$1.7b since Q2 2024. See our latest analysis for RenaissanceRe Holdings. At a share price of US$271.89, RenaissanceRe has seen a 90 day share price return of 8.34%, while the 1 year total shareholder return of 6.49% and 5 year...

LendingClub (LC) is back on investors’ radar after recent sector coverage highlighted its performance against larger banks, with media reports pointing to solid profitability as well as revenue and EPS growth as peers faced earnings related selling. See our latest analysis for LendingClub. The recent media attention comes as LendingClub’s share price has gained 32.29% over the past 90 days and 7.27% over the last month, while its 1 year total shareholder return of 24.68% and 3 year total...

Cloudflare (NET) has moved deeper into the AI economy by acquiring Human Native, an AI data marketplace. The company is also rolling out tools to block unauthorized AI crawlers and has published its 2026 App Innovation Report on modernization and security. See our latest analysis for Cloudflare. Despite the flurry of AI focused announcements, Cloudflare’s recent share price has cooled, with a 30 day share price return of a 6.8% decline and a 90 day share price return of a 12.3% decline...

In recent weeks, Albemarle Corporation has drawn heightened attention as it prepared for its Future Minerals Forum 2026 presentation in Riyadh and scheduled the release of its fourth-quarter 2025 earnings for February 11, 2026, alongside a follow-up conference call. At the same time, a wave of analyst upgrades and improving earnings expectations, tied to a more optimistic view of the lithium market, has reshaped how many market participants view Albemarle’s prospects and risk profile. Next,...

If you are wondering whether City Holding at around US$123.51 is offering fair value or a potential mispricing, you are in the right place. The stock has been relatively steady in the short term, with a 0.2% decline over 7 days and a 1.8% decline over 30 days, while the longer-term picture shows returns of 3.0% year to date, 6.7% over 1 year, 50.6% over 3 years and 101.4% over 5 years. Recent coverage of City Holding has centered on its position in the regional banking space and how...

If you are wondering whether Caterpillar's current share price lines up with its underlying value, you are not alone. That is exactly what this article will help you unpack. Caterpillar's stock last closed at US$647.18, with returns of 6.4% over 7 days, 9.9% over 30 days, 8.1% year to date and 72.6% over 1 year, plus 175.9% over 3 years and 268.4% over 5 years. These figures naturally raise questions about what is already priced in. Recent coverage has focused on Caterpillar's role in large...

Why Henry Schein Is on Investors’ Radar Today Henry Schein (HSIC) has drawn fresh attention after recent share price moves, with the stock last closing at US$78.08. For investors, the key question is how this price lines up with the company’s fundamentals. See our latest analysis for Henry Schein. Recent trading has been mixed, with a 2.39% 1 day share price return and a 23.98% 90 day share price return. The 1 year total shareholder return of 8.82% and 3 year total shareholder return of a...

Earlier this week, the Trump administration announced a mortgage-bond buying plan intended to push mortgage rates lower by roughly offsetting the Federal Reserve’s monthly runoff of mortgage-backed securities. For Meritage Homes, a builder focused on new single-family housing, any sustained easing in mortgage costs could meaningfully influence buyer affordability and order activity ahead of its January 28 fourth-quarter results release. We’ll now examine how the administration’s push for...

In January 2026, PensionBee and SS&C Technologies Holdings expanded their partnership, allowing customers using SS&C's RolloverCentral platform to move old 401(k) accounts directly into PensionBee IRAs through a secure, automated process that removes paperwork and manual checks. This move highlights SS&C’s role as a core infrastructure provider in retirement account transfers, embedding its technology more deeply into the US roll‑over ecosystem. We’ll now consider how embedding SS&C’s...

We look at whether Macy's at around US$21.57 still offers value after a strong run, or whether most of the easy gains may already be behind it. The stock has pulled back with a 9.1% decline over the last 7 days and a 6.7% decline over the last 30 days, while the 1-year return is 63.0% and the 5-year return is 108.3%. Recent headlines around Macy's have focused on its role as a major US department store and ongoing interest from investors who are watching how traditional retailers are...

In recent days, Raymond James initiated coverage on BankUnited with an Outperform rating, joining a flurry of analyst updates and reaffirmed views from other brokerage firms. Amid this increased analyst attention, the stock now sits between differing viewpoints, with individual firms growing more positive even as the broader consensus remains cautious. Next, we’ll examine how this new Raymond James Outperform initiation and broader analyst reappraisal could reshape BankUnited’s existing...

Summit Therapeutics has submitted a Biologics License Application to the FDA for ivonescimab plus chemotherapy in EGFR‑mutated non-squamous non-small cell lung cancer and separately entered a clinical trial collaboration with GSK to test ivonescimab with GSK’s B7‑H3 antibody-drug conjugate across several solid tumors, including small cell lung cancer. Together, these steps deepen ivonescimab’s clinical footprint across lung and other solid tumors, positioning Summit as a more central player...

If you are wondering whether FIGS shares still offer value after a strong run, this article walks through how the current price lines up against different valuation checks. FIGS recently closed at US$12.33, with returns of 4.5% over 7 days, 4.1% over 30 days, 8.3% year to date, and 101.5% over the last year, which can change how investors think about both opportunity and risk. Recent coverage has focused on FIGS as a branded healthcare apparel company listed on the NYSE. Investors are paying...

First Horizon (FHN) just closed out FY 2025 with fourth quarter revenue of US$888 million and basic EPS of US$0.52, capping a twelve month run that produced US$3.36 billion in revenue and basic EPS of US$1.89. Over that period, revenue moved from US$3.04 billion to US$3.36 billion and basic EPS went from US$1.37 to US$1.89. Trailing net income reached US$956 million, giving investors a set of results anchored by thicker profit margins and a clearer earnings profile to weigh against future...

Kymera Therapeutics has outlined past and upcoming milestones across its oral immunology pipeline, including launching the BREADTH Phase 2b trial of KT-621 in eosinophilic asthma and reporting earlier positive Phase 1b data in atopic dermatitis. The company’s expanded clinical agenda, together with progress on partnered programs such as the IRAK4 degrader with Sanofi and an option-based collaboration with Gilead, highlights growing external interest in its targeted protein degradation...